Subscribe to Money Morning get daily headlines subscribe now! Money Morning Private Briefing today's private briefing Access Your Profit Alerts

This Bioscience Company Has "Nearly Limitless" Income Potential

Medical device companies can be profit-making machines – one manufacturer of magnetic resonance imaging (MRI) machines and other high-tech products is up more than 250% over the past 12 months, for instance.

Most of them make their living by staying on the leading edge of innovation, producing some of the coolest gadgets you can imagine.

And, even better, they can deliver some of the most impressive gains in the bioscience industry to their shareholders.

The good performance of these manufacturers gives you some idea of the potential we're dealing with here.

Just look at these soaring share prices…

These Three Companies Have Easily Beaten the Markets

Boston Scientific Corp. (NYSE: BSX) develops, manufactures, and markets medical devices for the cardiology markets, including stents, balloon catheters, wires, and peripheral embolization devices, among many, many other items. The company also makes products to treat diseases of the digestive, urinary, and pulmonary (lung) systems. Boston Scientific is up 40% over its price this time last year.

Hologic Inc. (Nasdaq: HOLX) makes a broad array of diagnostics products, medical imaging systems, and surgical products for women, such as digital and film-based mammography systems, computer-aided detection (CAD) for mammography, invasive breast biopsy devices, breast biopsy site markers, breast biopsy guidance systems, and breast brachytherapy products (radioactive inserts). Hologic shares are currently up 64% over their value one year ago.

IRadimed Corp. (Nasdaq: IRMD) develops, manufactures, markets, and distributes magnetic resonance imaging (MRI) compatible products in the United States and internationally. It offers non-magnetic intravenous (IV) infusion pump systems and accessories, wireless remote displays/controls under the mRidium name, sidecar pumps, and dose error reduction systems, among many other products. IRMD stock is up a whopping 250% over the past 12 months.

This Is a Big Market – and It's Getting Bigger

Although medical device companies and biotechs that develop new drugs play on similar fields, there are significant differences both in the markets they target and in the regulatory process they undergo. It's important for investors to understand these differences when choosing where to put their capital.

Join the conversation. Click here to jump to comments…

About the Author

Ernie Tremblay has more than 25 years of experience in following and analyzing the latest developments in health, medicine, and related technologies. He understands the FDA approval process, as well as the "hard science" behind new, experimental drugs and the market demand for them - and has a comprehensive grasp of the complex dynamics that determine whether a new drug will be a breakthrough winner, or just another casualty of the FDA approval process.

Read full bio

  1. Mark Byrley | August 8, 2015

    What happened to the stock that held the testing kit for the 59 second disease that Obama was to urge everyone to get tested for? The stock where insiders owned 90% of the float?

  2. David Agami | August 8, 2015

    Can you please tell me if there are any "key dates" for reports of AERIE and CUR, and your comments on these two companies?
    Regards, David

  3. Ernie Tremblay | August 11, 2015

    Mark, as of session close today, August 10, it is up 13.65 percent over our entry point. Thanks for asking.

  4. Ernie Tremblay | August 11, 2015

    David, because both of these stocks are in the portfolio of our paid service, Biotech Insider Alert, I'm afraid I can't comment on them here. My apologies.

  5. Martin Cohen | August 12, 2015

    You might want to take a look at Biolase Technology (BIOL), the global leader in dental laser technology: Upgraded product line, major institutional capital infusion, new CEO with top dental background, expanded global marketing, very large global market entering expansion stage, base building at low end of the market. Worst case would appear to be a sale of the company at current or higher value, best case is a major breakout over the next12-24 months

    • Ernie Tremblay | August 13, 2015

      Martin, thanks for the recommendation! Always appreciated. I'll take a close look at BIOL. Sounds very interesting.

  6. LAWSON22350 | July 2, 2016

    Can you tell me what's wrong with the biotech company PharmaCyte (PMCB)?
    They eliminate the problem of nausea from chemo treatment, have developed strong leadership and is at the forefront of treatment for pancreatic cancer involving encapsulating 'genetically' modified human cells (patented) that convert an inactive chemotherapy drug into its active or “cancer-killing” form. They are at the forefront of medical marijuna testing. Having also found the 'holy grail' of eliminating the pain from acidic buildup in the stomach and having diabetes treatment that only requires an annual shot. They are opening phase 2b testing for pancreatic cancer (phase 1 beat the current gold treatment) and soon after that for diabetes phase 1 begins.
    but there stock seems to be stuck.

Leave a Reply

Your email address will not be published. Required fields are marked *

Some HTML is OK